NTV Asset Management’s VanEck Pharmaceutical ETF PPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$661K Buy
6,033
+214
+4% +$23.9K 0.06% 196
2026
Q2
$636K Buy
5,819
+104
+2% +$10.8K 0.06% 197
2026
Q1
$594K Buy
5,715
+14
+0.2% +$1.49K 0.07% 194
2025
Q4
$588K Buy
5,701
+599
+12% +$58.3K 0.06% 189
2025
Q3
$461K Sell
5,102
-2,855
-36% -$250K 0.05% 211
2025
Q2
$700K Sell
7,957
-1,215
-13% -$105K 0.08% 165
2025
Q1
$836K Buy
9,172
+1,463
+19% +$132K 0.11% 134
2024
Q4
$665K Buy
7,709
+271
+4% +$24.5K 0.09% 153
2024
Q3
$707K Buy
7,438
+341
+5% +$32.4K 0.09% 149
2024
Q2
$649K Buy
7,097
+2,102
+42% +$188K 0.09% 150
2024
Q1
$453K Buy
+4,995
New +$437K 0.07% 174
2023
Q1
– Sell
-2,600
Closed -$202K – 254
2022
Q4
$202K Buy
+2,600
New +$192K 0.04% 240
2016
Q4
– Sell
-4,850
Closed -$278K – 158
2016
Q3
$278K Sell
4,850
-800
-14% -$48K 0.1% 145
2016
Q2
$331K Sell
5,650
-300
-5% -$17.5K 0.13% 132
2016
Q1
$342K Hold
5,950
– – 0.13% 134
2015
Q4
$388K Hold
5,950
– – 0.15% 128
2015
Q3
$374K Hold
5,950
– – 0.12% 154
2015
Q2
$420K Buy
+5,950
New +$428K 0.12% 153

Other funds holding PPH

NTV Asset Management's PPH Position: Q3 2026 in Review

NTV Asset Management increased its VanEck Pharmaceutical ETF (PPH) stake by 3.7% in Q3 2026, buying an estimated $23.9K and bringing the position to 6,033 shares worth $661K. The position accounts for 0.06% of the portfolio, ranked #196.

NTV Asset Management first reported a position in PPH in Q2 2015 and has held it in 18 quarters since. The position peaked at $836K in Q1 2025. 116 funds tracked by Wall St. Rank hold PPH as of Q3 2026.

  • NTV Asset Management held 6,033 shares of VanEck Pharmaceutical ETF worth $661K as of Q3 2026.
  • NTV Asset Management bought 214 VanEck Pharmaceutical ETF shares in Q3 2026, an estimated $23.9K.
  • VanEck Pharmaceutical ETF made up 0.06% of NTV Asset Management's portfolio in Q3 2026, its #196 holding.
  • NTV Asset Management first reported a position in VanEck Pharmaceutical ETF in Q2 2015 and has held it in 18 quarters since.
  • NTV Asset Management's VanEck Pharmaceutical ETF position peaked at $836K in Q1 2025.
  • 116 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q3 2026.

Based on NTV Asset Management's 13F filing for Q3 2026, filed 23 Oct 2026.